Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Lisa Hinterwimmer"'
Autor:
Abhishek S. Kashyap, Tamara Thelemann, Richard Klar, Sandra M. Kallert, Julia Festag, Melanie Buchi, Lisa Hinterwimmer, Monika Schell, Sven Michel, Frank Jaschinski, Alfred Zippelius
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-12 (2019)
Abstract Background Cancer cells are known to develop mechanisms to circumvent effective anti-tumor immunity. The two ectonucleotidases CD39 and CD73 are promising drug targets, as they act in concert to convert extracellular immune-stimulating ATP t
Externí odkaz:
https://doaj.org/article/270e5351314041b4b9b45ed11b5860ce
Autor:
Lisa Hinterwimmer, Richard Klar, Sven Michel, Frank Jaschinski, Alfred Zippelius, Monika Schell
Publikováno v:
Cancer immunology, immunotherapy : CII. 69(1)
Tumors can utilize a diverse repertoire of immunosuppressive mechanisms to evade attack by the immune system. Despite promising success with blockade of immune checkpoints like PD-1 the majority of patients does not respond to current immunotherapies
Autor:
Frank Jaschinski, Melanie Buchi, Tamara Thelemann, Lisa Hinterwimmer, Monika Schell, Sven Michel, Abhishek S. Kashyap, Alfred Zippelius, Sandra M. Kallert, Julia Festag, Richard Klar
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 7, Iss 1, Pp 1-12 (2019)
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer
Background Cancer cells are known to develop mechanisms to circumvent effective anti-tumor immunity. The two ectonucleotidases CD39 and CD73 are promising drug targets, as they act in concert to convert extracellular immune-stimulating ATP to adenosi
Autor:
Richard Klar, Stefanie Raith, Yu Cao, Eslam Mohamed, Frank Jaschinski, Lisa Hinterwimmer, Monika Schell, Paulo C. Rodriguez, Sven Michel
Publikováno v:
Cancer Research. 79:3275-3275
The microenvironment generated by tumor cells and suppressive stromal cells creates unfavorable conditions for effector immune cells in order to escape anti-tumor immunity. Besides suppressive pathways like for example the CD39/CD73 axis, mechanisms
Autor:
Julia Festag, Richard Klar, Melanie Buchi, Lisa Hinterwimmer, Monika Schell, Frank Jaschinski, Sandra Kallert, Sven Michel, Tamara Thelemann, Alfred Zippelius, Abhishek S. Kashyap, Stefanie Raith
Publikováno v:
Cancer Research. 79:5021-5021
The ectonucleotidases CD39 and CD73 have emerged as promising therapeutic targets to enhance antitumor immune responses, as they act in concert to convert extracellular immune-stimulating ATP to immunosuppressive adenosine. CD39 and CD73 are expresse
Autor:
Sandra M. Kallert, Lisa Hinterwimmer, Richard Klar, Frank Jaschinski, Monika Schell, Marina Van Ark, Tamara Hilmenyuk, Alfred Zippelius
Publikováno v:
Cancer Research. 78:5909-5909
During the last decades it became obvious that the immune system can be utilized to evoke effective antitumor responses. However, cancer cells develop mechanisms to circumvent this. The two ectonucleotidases CD39 and CD73 are promising drug targets,